Tag Archive for: esld

Resolution Therapeutics extends inflammatory and fibrotic disease pipeline with in vivo Regenerative Macrophage Therapy

/in

Material Transfer Agreements provide access to leading lipid nanoparticle formulations to validate delivery of its proprietary payloads and accelerate development of in vivo Regenerative Macrophage Therapy  Development programme complements Company’s autologous engineered Regenerative Macrophage Therapy, RTX001, in Ph 1/2 clinical development Together, programmes aim to broaden patient population able to benefit from Regenerative Macrophage Therapy  […]

Read more

Resolution Therapeutics congratulates University of Edinburgh on positive 4-year MATCH trial data on RMT in liver cirrhosis

/in

Results support progression of EMERALD clinical trial of Resolution’s engineered macrophage therapy, RTX001 Four-year follow-up data from the University of Edinburgh’s MATCH study, led by Resolution Therapeutics’ founder Professor Stuart Forbes, published in the journal Cell Stem Cell Resolution is pioneering engineered Regenerative Macrophage Therapy – which uses engineered macrophages designed to deliver a more […]

Read more

Resolution Therapeutics Announces Regenerative Macrophage Therapy (RMT) Manufacturing Process & Candidate Testing Suite at ASGCT 2025

/in

– Proprietary manufacturing process enables robust and scalable GMP-compliant manufacture of autologous engineered RMT products, including lead asset RTX001 in end-stage liver disease (ESLD). – Novel mode of action-based candidate testing suite enabled the discovery of RTX001, which shows enhanced anti-inflammatory and anti-fibrotic effects in vitro and in vivo. – The EMERALD Phase1/2 interventional study […]

Read more
© Optimum Strategic Communications.